FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

スタックライブラリ

Gut Repair Stack

Recovery & Healingbeginner

85

シナジー

85
Share
ペプチド

2

平均日用量mcg

1,000

レベル

beginner

追加

May 17, 2026

概要

The Gut Repair Stack targets the gastrointestinal system specifically, combining BPC-157''s mucosal healing properties with KPV''s potent anti-inflammatory action in the gut lining. This combination has become a go-to protocol for functional medicine practitioners working with IBS, Crohn''s disease, ulcerative colitis, SIBO, post-antibiotic gut damage, and leaky gut syndrome. BPC-157 was originally isolated from human gastric juice and was first studied for its effects on the gastrointestinal system. It promotes healing of the gut mucosa through multiple mechanisms: stimulating cell migration to damaged mucosal surfaces, increasing blood flow to the GI tract, and upregulating growth factor expression in intestinal tissue. Both oral and subcutaneous administration are used — oral BPC-157 is increasingly studied for direct GI application. KPV (Lys-Pro-Val) is a tripeptide fragment of alpha-MSH with direct anti-inflammatory effects in the gut. It targets NF-κB signaling, one of the primary inflammatory pathways driving IBD, Crohn''s, and colitis. Unlike systemic anti-inflammatory drugs, KPV acts preferentially in mucosal tissue and can cross the intestinal epithelium to reach submucosal immune cells. It also demonstrates antimicrobial properties that may support a healthier gut microbiome. Together, BPC-157 rebuilds the gut architecture while KPV quiets the immune over-activation that prevents healing. This is particularly powerful in chronic inflammatory gut conditions where the inflammatory environment actively disrupts mucosal repair. Users typically take KPV orally (capsule or liquid) and BPC-157 orally or subcutaneously depending on the condition being targeted.

投与プロトコル

BPC-157

Twice per day· oral or subcutaneous

BPC-157について詳しく読む →

250 mcg

1回の投与あたり

500 mcg

1回の投与あたり

目標と証拠

Gut healingIBS reliefLeaky gutIntestinal inflammationIBD support
証拠ランク:動物実験

警告

  • Oral BPC-157 has less bioavailability data than injectable. BPC-157 and KPV were removed from FDA Category 2 (April 2026) but remain under PCAC review (July 23, 2026) — not legal to compound yet.

Comments

Sign in to join the discussion

注意: このスタックはコミュニティから提出され、研究用のみです。Peptide Contactsは提出されたスタックの安全性や効果性を確認していません。使用するペプチドプロトコル前に常に資格のある医療専門家に相談してください。